Trimeris

Trimeris has appointed Martin A. Mattingly, Pharm.D. as chief executive officer. Dr. Mattingly will also join the Company’s board of directors.

Julian Baker, a member of the company’s board of directors, remarked, “The Trimeris Board is extremely excited by Martin’s decision to join the Company. His hands-on experience in commercializing HIV products in crowded markets and in maximizing the value of these products as they mature is an ideal fit for Trimeris. During his tenure at Agouron and Pfizer, Martin was actively involved in both the successful launch of Viracept and its life-cycle management as numerous competitors entered the market.”

Dr. Mattingly was most recently president and chief executive officer of Ambrx Pharmaceuticals. Prior to that, he served as executive vice president and chief operating officer at CancerVax. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals and Pfizer. These assignments included general manager for the Agouron HIV division; vice president, Product Development Group; and vice president, Global Marketing Planning. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Lilly.